43.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$42.99
Offen:
$42.83
24-Stunden-Volumen:
1.52M
Relative Volume:
1.00
Marktkapitalisierung:
$5.06B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-8.211
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
-4.93%
1M Leistung:
-8.98%
6M Leistung:
-17.48%
1J Leistung:
-38.40%
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CYTK
Cytokinetics Inc
|
43.19 | 5.06B | 18.47M | -589.53M | -399.80M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-07 | Eingeleitet | Citigroup | Buy |
2025-01-22 | Eingeleitet | Stifel | Buy |
2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
2024-01-24 | Herabstufung | UBS | Buy → Neutral |
2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2023-11-09 | Eingeleitet | Goldman | Buy |
2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
2023-08-15 | Eingeleitet | SVB Securities | Outperform |
2023-02-17 | Eingeleitet | BofA Securities | Neutral |
2022-12-23 | Bestätigt | Needham | Buy |
2022-12-20 | Eingeleitet | Truist | Buy |
2022-10-11 | Eingeleitet | UBS | Buy |
2022-01-28 | Eingeleitet | Goldman | Buy |
2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
2021-12-10 | Eingeleitet | JP Morgan | Overweight |
2021-10-07 | Eingeleitet | Jefferies | Buy |
2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
2021-02-18 | Eingeleitet | Barclays | Overweight |
2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
2020-10-29 | Eingeleitet | Goldman | Neutral |
2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
2020-05-05 | Eingeleitet | Mizuho | Buy |
2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
2016-07-28 | Bestätigt | Needham | Buy |
2015-11-10 | Bestätigt | FBR Capital | Outperform |
2015-11-09 | Bestätigt | ROTH Capital | Buy |
2015-07-24 | Bestätigt | MLV & Co | Buy |
2014-12-31 | Bestätigt | ROTH Capital | Buy |
2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy - Insider Monkey
Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - Marketscreener.com
Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - MSN
Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care - Nasdaq
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - The Manila Times
Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $87,160 in stock - Investing.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - Marketscreener.com
Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan
H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK
Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView
Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma
UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual ... - NRToday.com
Cytokinetics’ EVP sells $4,500 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com UK
Cytokinetics’ EVP sells $4,500 in stock - Investing.com India
Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa
Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com
Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK
Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia
Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada
Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks
RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks
Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks
Why Have Cytokinetics Stocks Plummeted? - TipRanks
Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks
Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com
Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks
Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World
B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World
Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com India
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise
Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com
Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India
Cytokinetics Executives Engage in Stock Transactions - TradingView
Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK
Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK
What is B. Riley’s Forecast for Cytokinetics Q1 Earnings? - Defense World
Cytokinetics assumed with an Overweight at Morgan Stanley - TipRanks
Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date - TipRanks
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):